Moderna’s new Laval-based facility supports onshore vaccine production, bolsters health and economic resilience, and ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...
It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal ...
Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with ...
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone ...
Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh ...
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
Timing and eligibility for the COVID-19 public vaccination program in Canada is set by each province and territory. Those who meet provincial criteria will receive COVID-19 vaccines free of charge.
Moderna (MRNA) announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the company’s investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback